• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

XOMA Royalty Corporation - Common Stock (NQ:XOMA)

40.17 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about XOMA Royalty Corporation - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
3 Crazy Good Stocks to Buy With $500 Right Now ↗
June 12, 2024
For investors with only a little money to spare, these three supercharged stocks represent an outrageous opportunity for future growth. 
Via InvestorPlace
News headline image
Peeling Back The Layers: Exploring XOMA Through Analyst Insights ↗
May 31, 2024
 
Via Benzinga
News headline image
XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ
May 14, 2024
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Stock Earnings: XOMA Misses EPS, Beats Revenue for Q1 2024 ↗
May 09, 2024
XOMA stock results show that XOMA missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities
May 09, 2024
From XOMA Corporation
Via GlobeNewswire
News headline image
Cracking The Code: Understanding Analyst Reviews For XOMA ↗
April 29, 2024
 
Via Benzinga
News headline image
Recap: XOMA Q4 Earnings ↗
March 08, 2024
 
Via Benzinga
News headline image
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%
April 30, 2024
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)
April 25, 2024
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Corporation Announces Closing of Tender Offer
April 03, 2024
Kinnate Stockholders to Receive $2.5879 Per Share in Cash Plus Contingent Value Right 
From XOMA Corporation
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE)
March 25, 2024
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
XOMA Declares Quarterly Preferred Stock Dividends
March 21, 2024
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.
March 19, 2024
Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio 
From XOMA Corporation
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq –
March 19, 2024
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Whole Earth Brands, Inc. (Nasdaq – FREE), Kinnate Biopharma Inc. (Nasdaq – KNTE), Societal CDMO Check Corp. (Nasdaq – SCTL), California BanCorp (Nasdaq – CALB)
March 13, 2024
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
XOMA Stock Earnings: XOMA Misses EPS, Misses Revenue for Q4 2023 ↗
March 08, 2024
XOMA stock results show that XOMA missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value
March 08, 2024
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA to Present at Upcoming Investor Conferences in March
February 28, 2024
From XOMA Corporation
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: VIZIO Holding Corp. (NYSE - VZIO), HireRight Holdings Corporation (NYSE – HRT), Kinnate Biopharma Inc. (Nasdaq – KNTE), California BanCorp (Nasdaq – CALB)
February 20, 2024
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Biotech Royalty Aggregator XOMA To Acquire Small Cancer-Drug Developer Kinnate Biopharma ↗
February 16, 2024
XOMA acquires Kinnate Biopharma for $2.3352 per share, with potential additional cash. The acquisition is expected to close in April 2024. 
Via Benzinga
News headline image
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right
February 16, 2024
Upon closing, XOMA anticipates adding approximately $9.5 million in cash to its balance sheet and several early-stage programs to potentially add to its royalty portfolio 
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
January 18, 2024
From XOMA Corporation
Via GlobeNewswire
News headline image
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx
January 11, 2024
FDA has acknowledged receipt of the resubmission and assigned a PDUFA target action date of June 21, 2024 
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors
January 08, 2024
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Announces Stock Repurchase Program of up to $50 Million
January 02, 2024
Balanced capital allocation strategy looks to return capital to shareholders while continuing to invest in royalty and milestone acquisitions that will drive total shareholder return 
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Declares Quarterly Preferred Stock Dividends
December 20, 2023
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties
December 19, 2023
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder Value
November 07, 2023
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
October 31, 2023
FDA has granted Priority Review and assigned a PDUFA target action date of April 30, 2024 
From XOMA Corporation
Via GlobeNewswire
News headline image
XOMA Declares Quarterly Preferred Stock Dividends
September 25, 2023
From XOMA Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap